Dr. Kenneth C. Waterman
President and Chairman of the Board
After receiving his B.S. (UCLA) and Ph.D. (UC Berkeley) in physical-organic chemistry, Kenneth Waterman completed post-doctoral studies (Columbia University) before spending 12 years at Polaroid (as a distinguished scientist), then 13 years at Pfizer (as a Research Fellow). He has successfully invented and commercialized a number of products and is the author of over 75 publications. He was made an AAPS Fellow in 2011 the same year he started FreeThink Technologies.
Vice President and Secretary of Board
Mark Kastan received his B.A. (Washington University) and MBA (University of Rochester). He worked on Wall Street for 17 years (Credit Suisse First Boston, Merrill Lynch) as an equity analyst. He helped found FreeThink Technologies in 2011 and currently heads the software division and manages company finances.
Dr. Alisa Waterman
Chief Science Officer and Member of Board
Alisa Waterman received her B.A. (Wesleyan University) and Ph.D. (Albert Einstein College of Medicine), and completed post-doctoral studies (Yale University) before spending 24 years at Boehringer Ingelheim (as a Senior Research Fellow) championing discovery and development of biological and small molecule drug candidates. In 2015 she joined FreeThink Technologies where she currently manages the customer portfolio of projects.
Dr. Jennifer Chu
Technology Development Lead
Jennifer Chu received her B.S.E. (Princeton University) and Ph.D. (University of Texas, Austin) before spending 7 years at Pfizer (as a Senior Principal Scientist) followed by work at a series of small biotech companies (Neurogen, Ikaria, Achillion as an Executive Director of Pharmaceutical Sciences). She joined FreeThink in 2018 where she leads formulation development and manages FreeThink’s new technology development.
Business Development Manager
Dave received his B.S. from Springfield College and has >20 years of pharmaceutical industry experience, including pharmaceutical sciences supply chain management and clinical development operations. While at Pfizer, Dave was a senior leader on the industry's first full-scale flexible resource model for global clinical trial management, and in 2013 he founded the consulting firm Verdure Bay to offer flexible expertise in product development. Dave joined FreeThink in 2018 to help lead global business development strategy and execution.
Dr. Larry Mallis
Director of Analytical Sciences
After receiving his B.S. (Rutgers University) and Ph.D. (Texas A&M University) in analytical chemistry – mass spectrometry, Larry Mallis was Director of the High Resolution Mass Spectrometry Facility at the University of Iowa for 5 years. This was followed by 20 years at a series of pharmaceutical companies (Bristol-Myers Squibb, Wyeth Research, and Merck) developing a variety of analytical techniques in support of Discovery, Toxicology, and Development of a variety of new drug substances and drug products. Over the last 10 years, he has been working in the contract research industry in support of biological and small molecule drug candidates, in the pharmaceutical and crop protection industries. In 2021, he joined FreeThink where he leads the analytical sciences department.
Dr. Patrick Kelleher
Associate Director, Physical Sciences
Patrick Kelleher received his B.S. (Stonehill College) and Ph.D. (Yale University) in physical chemistry before completing post-doctoral studies at the University of Virginia. His graduate and post-doctoral work focused on the development of spectroscopic and mass-spectrometric techniques for structural elucidation of small molecules. Patrick joined FreeThink in 2020 where he currently leads the physical sciences department.
Member of Board
Richard Waterman is owner of the accounting firm Waterman and Associates. He received his B.S.E. (UCLA) and MBA in accounting (San Jose State). He is a member of the Campbell, California city council. He advises FreeThink on financial matters.